Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary

August 8, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 45 min

Earnings Call Speaker Segments

Elizabeth Krutoholow

executive
#1

Thanks, everyone, and good morning. It's great to have you with us for Tempus's conference call covering the second quarter of 2025. Earlier today, Tempus shared its results for the quarter that closed on June 30, 2025. You can find the press release, a summary of the quarter, and our newest presentation over on our IR website. With me here today from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to note that on this call, management might make forward-looking statements. Those statements carry risks and uncertainties, and actual results could end up differing materially. For a fuller discussion of those risks, please see our 10-K and the other filings we've made with the SEC since then. Also during this call, we'll be talking about non-GAAP financial measures, which aren't put together in line with generally accepted accounting principles. You can find definitions of these non-GAAP financial measures, plus reconciliations to the GAAP financial measures that are most directly comparable, inside our earnings release. That release has been furnished to the SEC and is posted on our website at investors.tempus.com. At this point, I'd like to hand the call over to Eric.

Eric Lefkofsky

executive
#2

Good morning, everybody. I'll give you a brief rundown. The second quarter was an outstanding one. As I said in my letter, we're really hitting our stride as we get close to marking 10 years since the company was founded, which feels terrific. Revenue rose 89.6%, reaching $314.6 million. Genomics revenue climbed 115% to $241.8 million, driven by accelerating volume growth in oncology, which moved up from roughly 20% in the prior quarter to 26% in this one, and that was wonderful to see. Our ad testing came in at 32% for the quarter. Aid in services revenue was up 35.7%, landing at approximately $73 million, powered by Insights — that's our data licensing business — which expanded by nearly 41%. Gross profit for the quarter totaled $195 million, an increase of about 160%. While the business expands, we remain disciplined regarding the investments we make. Because of that, we posted yet another sequential gain in Adjusted EBITDA, which moved from approximately — $16 million in the previous quarter to — $5.6 million in this one. We're getting close to Adjusted EBITDA breakeven. We raised our full year 2025 revenue guidance to $1.26 billion and kept our Adjusted EBITDA projection of roughly $5 million for the year, which would represent an improvement of about $110 million versus last year. We strengthened the balance sheet as well. We issued $750 million of 0.75% convertible notes, which will lower interest expense and generate substantial cash savings. That, combined with our cash and marketable securities ending the quarter at roughly $290 million, and net of that, after paying down some of the debt, as I noted, we added about $375 million more, puts our balance sheet in a truly strong position heading into Q3. Taken together, the business is exactly where we want it, and we're making excellent progress; with that, I'm happy to take questions.

Dan Brennan

analyst
#3

Great, thanks. I'm grateful for the chance to ask. Nice work on this quarter. I'll start with several questions at once. Eric, could you start by giving us more detail about how well core genomic volumes did during the period? In your prepared remarks, you mentioned gains in sales force productivity. Any additional insight on what drove that strength — was it tissue rather than blood, expansion of the overall market, or taking share from competitors? Turning to Ambry, that was a really impressive quarter. Your script noted that the volume projection in the deal model might be too conservative. What are you observing on that front? You also brought up rare genetic disease in children. Is that already adding to results today? To wrap up, Insights had a strong quarter with 40% growth. Could you give us any detail on how Pathos is performing? I noticed in the written script you mentioned it's contributing. I'm just curious how that's progressing, and if you have any information on bookings, that would be great as well. Thanks.

Eric Lefkofsky

executive
#4

Yes, there's quite a bit to cover there. I'll begin at the start. Perhaps Jim can chime in at the end. We experienced considerable sequential volume growth throughout our whole oncology testing compendium. It was extensive. It wasn't limited to solid or liquid. It truly spanned everything; it was remarkable. A lot of what drove this came from steps we'd already taken — making our sales force more efficient, shifting some territory boundaries, and upgrading various parts of our technology stack. During Q2, many of those efforts simply started bearing fruit. It's genuinely encouraging to witness such robust volume growth, and that's precisely the outcome you hope for. When a set of initiatives begins returning benefits, it gives you confidence they'll hold up over time. Within our oncology business, we believe we're positioned very well. On top of that, hereditary volumes came in substantially above what we had anticipated. They aren't showing any signals of easing up anytime soon either. A handful of segments are driving this expansion. Part of it stems from the simple fact that certain long-standing competitors in that market have seen their share shrink; a great deal of that volume is landing with us; beyond that, the whole category seems to be enjoying some genuinely strong tailwinds. This aligns with what I mentioned in my letter. At the time we bought Ambry, our expectation was that this market would grow considerably over the years. The prevailing view was that it was approaching a point of saturation and maturity, yet our consistent position has been that this view is completely mistaken. That's what we continue to believe. The number of individuals who could develop cancer or some other illness is simply much larger than the number who already have a disease. To be honest, I wouldn't be surprised in the least if the volume generated by hereditary sequencing turns out to be substantially greater than what cancer sequencing brings in, or sequencing for any one disease, for that matter. Beyond that, their performance in rare disease and pediatrics is strong — in that space, they hold basically the number two position. Yes, it's a modest segment, but it's growing pretty rapidly. My expectation is that, over time, this portion of the business will continue to expand as well. Taking everything together, the testing side of things was simply very strong right across the board. Now, when it comes to our data business, that one is also enjoying its moment. As everyone knows, we closed a really big deal to construct a foundation model — that's incredibly exciting; it's currently being built; and we've got excellent line of sight into the rest of the year, which is exactly the position you want to be in. It comes down to the law of large numbers, doesn't it? When it comes to our growth rate, well, we aren't going to keep expanding that business at 80%. That simply won't happen. Our message to everyone has been consistent: we're targeting growth to stay around 25% or 30%. We exceeded that mark this quarter, which is great news. Broadly speaking, when you consider the company's two main drivers — sequencing diagnostics and data — we're in a truly solid spot.

Yuko Oku

analyst
#5

Hi there. Thanks for taking my questions. You've already achieved a lot in the first half moving xT volumes over to CDX, and there's also the ASP drag coming from XMRAMP, so how should we think about the cadence of ASP on the way toward that goal of getting 40% of xT volume onto CDX by the time the year ends? And separately, even though you have a whole transcriptome RNA panel, a few of your peers are putting extra features onto their tissue therapy selection test, like RNA and epigenomic markers. Might that be something you'd consider down the road?

Jim Rogers

executive
#6

Yeah, I'll handle the first one on ASP, and then Eric can talk about future products. On ASP, like we said in the letter, we saw xT CDX volume go up. In Q1 it was roughly 20% of our xT volume, and it grew to roughly 28% in Q2. As you noted, we're aiming to reach 40% by the end of the year. During Q2, we saw a mix shift toward some of our lower dollar or lower reimbursement assays — XM, for which we don't have reimbursement right now, and xT as well. Our thinking is that over the rest of the year, as we get closer to 40%, you'd see incremental gains to overall ASPs. On the XM side, that will keep growing too. We're still gating that volume; we don't expect XM to offset all of the gains we have. We won't get a big step up like we had in Q1; we'd expect small incremental gains over the rest of the year.

Eric Lefkofsky

executive
#7

When it comes to RNA sequencing, we've actually performed whole transcriptome sequencing right from day one — that's simply how we kicked things off when our lab first launched. On the genomics side, targeted panel sequencing was always our approach, while on the RNA side we did whole transcriptome. We were early leaders in this area of performing whole transcriptome sequencing using FFP slides. Our panel is extremely comprehensive. Beyond essentially reporting expression levels across the full transcriptome, we additionally perform TCR profiling with that assay, plus BCR profiling and HLA typing; we've got an entire collection of algorithms that come out of it as well. Ultimately, it's simply a very comprehensive panel. My sense is that the probable improvements we'll see will lean more toward the DNA side in the future, as we shift from targeted panel sequencing toward whole genome sequencing gradually; if you look ahead 5 or 10 years, my guess is that targeted panels will mostly disappear, and instead people will simply run whole genome and whole transcriptome while adding other markers into those assays, such as epigenomic or methylation markers.

Yuko Oku

analyst
#8

Thanks.

Rachel Vatnsdal

analyst
#9

Great. Morning, everyone. Appreciate you fielding our questions. I'd like to explore the trials and Insights segments a bit more. To begin, could you describe the booking trends we saw this quarter in Insights and trials? Are there signs of softness coming from pharma, given certain headlines around MFN and tariffs, or from biotech clients facing funding limitations? Regarding Pathos, some detail would be helpful — it appears revenue there came to roughly $16 million for the quarter. What's the expected trajectory as we move through the second half of the year?

Eric Lefkofsky

executive
#10

Sure, I'll kick things off. Jim can address Pathos and AC revenue. Bookings were clearly very robust this quarter, since the AstraZeneca and Pathos transaction actually closed in April. From a bookings standpoint, Q2 saw a substantial figure. Our total contract value, reported only once a year, has risen significantly, as you'd expect, thanks to that transaction. We're positioned well when we consider total contract value heading into the latter part of the year. We've surpassed our targets, so we're sitting in a strong position given our ambitious goals. The clinical side — the trials booking operation — has never been a major contributor to bookings, our clinical trial management operation, mostly because if we assist in enrolling 10% or 15% of a U.S. trial, that could amount to 10 patients or 20 patients or 30 patients or 5 patients or whatever; at this point it simply isn't a major dollar contributor. Should that operation grow, it could turn into a larger figure. For now, it remains quite modest. It's extremely important for our relationships with biotech and pharma, and equally important for our relationships with providers. We've shared that we now connect with over 4,500 providers and institutions nationwide, which is clearly an enormous figure. These connections run deep. They're essentially two-way connections, with people permitting us to pull data in; we produce insights or diagnostics and then feed that information back. Part of this involves asking: can we examine healthcare data in real time — essentially data drawn from these electronic healthcare records? Can we accomplish genuinely valuable things with that data, such as spotting patients who could be an ideal match for a clinical trial, or finding a care gap that, for some reason, was overlooked and has put the patient on the wrong track? We're increasingly doing exactly that, meaning the critical role we fill keeps expanding. In my view, the clinical trials time operation is in a really strong position, and so is our next algos operation. They're simply fairly small at present, as we've noted historically regarding revenue and bookings.

Jim Rogers

executive
#11

Right, regarding that AstraZeneca Pathos agreement — as far as what it adds during the second half of the year, clearly we didn't capture a whole quarter of revenue from it in Q2, because of when that deal was signed. You'll see a modest sequential increase, though on a quarterly basis across the back half you should expect amounts in a comparable range.

Michael Ryskin

analyst
#12

Hey, I want to pick up where we left off on that previous topic. I'm just curious — over the past couple of years, you've struck a number of significant partnerships and investments with pharma companies. What does that pipeline look like going forward? I mean, clearly, I'm referring to the data and Insights platform business. I'd like to know how that pipeline is shaping up ahead, specifically regarding the large pharma players and how willing they are to keep putting money into data, especially now that more and more other genomics vendors are coming into the space. If I may add a second question to that, there's obviously been a lot of attention on profitability and EBITDA, and you showed progress this quarter. I'd like to hear you walk through what your investment priorities are going forward. How will you strike a balance across the different areas of the business when deciding where the incremental dollar goes? Thanks.

Eric Lefkofsky

executive
#13

Yeah, I'll kick things off. Jim might want to chime in as well. As far as our pipeline goes, it remains extremely strong. As we've mentioned before, the only genuine market impact we ever experienced came several years back, when biotech funding basically dried up, and we simply lost a massive group of customers that in 2022 were flushed with cash because they all went public; we're long past that. That's long in the rearview mirror. If anything, I would hope as the markets improve, some of these biotechs may actually be able to raise capital again, which would create a whole new source of potential data clients. When it comes to the big pharma companies, we still have a very healthy, robust pipeline of really large deals that we anticipate closing over some span of time. The main reason is that even if big pharma R&D budgets are being trimmed or come under pressure, data and AI and technology remain such a tiny piece of those multi-billion dollar budgets that we're simply not, we're not the item that gets cut. They might choose not to make an investment, but they could decline that investment even during strong periods. If they're looking to put money into AI or data, and they have a $9 billion R&D spend, a $100 million investment spread over several years won't concern them. We haven't experienced any pressure; nor have we experienced any pressure from rivals in that area. Honestly, whenever we lose a deal, it's essentially because a company decides not to move forward and make an investment, not because someone else has a product like ours. While we do have very strong competitors in the diagnostic space — companies at scale that do a perfectly good job sequencing patients — we simply don't sense those same competitors in the data and AI space. We just don't run into them. We haven't seen them. That hasn't changed recently. The situation could shift down the road, yet as things stand right now that isn't what's happening. On the investment side, I'll kick things off, and Jim is welcome to chime in whenever. This is one of those matters we'll need to work through carefully. As our 10th anniversary drew near, it mattered to us that we could create a company expanding rapidly while still producing operating leverage and reaching Adjusted EBITDA breakeven. In my letter I noted that what makes me especially proud is having a company that's scaling meaningfully and expanding more than 30%, all while continuing to deliver quarter-over-quarter gains, unlike plenty of others whose growth may even be slower and who aren't achieving that leverage; for us, substantial losses persist without any turnaround appearing on the horizon. Growing while staying disciplined is something we're handling quite well. My expectation is that we remain disciplined until Adjusted EBITDA turns positive and cash flow turns positive; we haven't reached a stage where we're simply reaping profits. We remain at a stage where we're pouring substantial resources into expansion. I'd guess we'll keep pouring substantial resources into expansion across the coming several years, because of how large the space is and because, as leaders in delivering AI to diagnostics and healthcare at large, plus given how big the market is, the very last thing we'd want is to essentially chase near-term optimization and let the long-term opportunity slip away.

Jim Rogers

executive
#14

Yes, I'd simply mention that nothing out of the ordinary is being done to achieve this level of leverage in the business. Considerable investments are being made in the genomics business, in data, and on the AI side. In our view, the amount of investment we're putting in at present is suitable. We wouldn't speed it up, clearly given the leverage we're realizing from the business, but we're definitely not starving the business just to show this improvement.

Ryan MacDonald

analyst
#15

Hi, Eric and Jim, congratulations on the fantastic quarter. I've got one about the data business and one about genomics. On data, it's wonderful to hear that work has begun on creating the foundational model and running some training here. I'm just wondering, regarding the added demand you're seeing from other partners at present who want to build something comparable here — clearly, you'll have what amounts to a first version ready in early 2026, but with AI investment moving so quickly, is waiting for what we might call proof of concept in early 2026 something other partners can really afford to do? On genomics, the MRD portfolio certainly appears to be landing well across the industry. I'm just wondering when we might see the larger unlock arrive via MolDX reimbursement, and whether that should be expected as a second half of 2025 event or one in 2026. Thanks.

Eric Lefkofsky

executive
#16

Yeah, I'll begin. I believe that's among the excellent questions we ourselves are spending considerable time considering. We're having quite substantive discussions with numerous parties who are contemplating developing models like the one AstraZeneca and Pathos are developing. To date, clearly, nothing has been announced by us. One thing we ask that group is precisely what you raised: in a world where models of this kind are apt to be transformative — not only for your R&D portfolio but also for the drugs you already sell — can you really afford to remain on the sidelines? I don't think that's something people are truly paying attention to. We pointed to it somewhat in the letter. One expectation we'd have from this model is that you're ingesting a tremendous volume of data, correct? We stated that we possess more than 350 petabytes of connected clinical molecular data; it's simply an enormous data repository. Essentially, you're performing compute for months on a cluster exceeding 1,000 H200s, and that's no small amount of capacity. You're discussing hundreds of billions of tokens over which you're performing compute. You're probably going to uncover connections that simply were invisible until you performed that quantity of compute. Such connections will probably be things like: when a patient carries this specific mutation, even if going on X, Y, or Z drug might be standard of care, we know typically half the population fails to respond to that drug. Even inside that, response exists along gradients. There are 20% of people who could be super responders, and 20% of people who never respond, plus some group in between. As things stand, these drugs are quite brute. They're like: I have a mutation, or there's a biomarker, or perhaps not even a biomarker, and I get a drug approved and give it to everyone. The way I see it, what artificial intelligence will probably accomplish — and what these foundation models ought to accomplish — is deliver insights to doctors and their patients about who is likely to have a response and who isn't. My guess is that this will bring about a fundamental shift in care, and likely far quicker than the guidelines are able to keep up, since those guidelines were designed around humans, not around AI. It's my suspicion that AI will generate some truly major disruption in this space. Whenever disruption of any kind shows up, you've got to sort of ask yourself: am I looking to be the one doing the disrupting, or the one getting disrupted? Seeing AstraZeneca take the lead on that was really cool, and my hunch is that other companies will follow. Eventually, I believe everybody will. I simply can't picture a world where folks say, no thanks, I don't want that sort of data, I'll just keep doing things the old way. My sense is that over the long haul, plenty of companies will either build comparable models or make use of comparable models, and shift meaningful dollars away from the chemistry and biology of the past toward data and AI. We will definitely be — or at least I'd expect us to be — a major beneficiary of that shift. The unknown is whether that plays out within a quarter or two, or three, or four. That kind of visibility simply isn't something we have. What we can see is the business doing quite well in the near term, thanks to things we signed previously. We're lucky that generating really strong growth doesn't require us to sign anything new down the road. On the subject of MRD — and then I'll hand things over to Jim — I'll talk about the volumes, and he can address the question of when it becomes a larger event. Our MRD portfolio is genuinely strong. It's broad in the sense that we offer both tumor-naive and tumor-informed products. It's broad in the sense that we're present across several disease areas: breast cancer, lung cancer, IO response, and CRC. We cover quite a wide range of assays in that market, and it's an exciting market that's expanding; having said that, we're holding back on volumes until reimbursement comes through, and perhaps you could give a bit of context around that.

Jim Rogers

executive
#17

Right, we've said before that we expect reimbursement to come through by the close of 2025. Nothing has shifted regarding our assay. Personalis has made their timeline public too. The guidance does not factor in any significant rise in MRD revenue for 2025; our expectation is that this shows up more during 2026.

Ryan MacDonald

analyst
#18

Thanks for the additional detail. Appreciate it.

Dan Arias

analyst
#19

Morning, everyone. Thank you. Jim, regarding data, could you give us a sense of what to expect for the second half? Clearly strong expansion during the quarter, yet it's declining a bit on a sequential basis coming off the close of last year. Comparisons become much tougher in 3Q and 4Q. In fact, 3Q presents a fairly demanding comparison. What's your view on where growth will settle in the latter half? Is modeling something above 30% still reasonable?

Jim Rogers

executive
#20

Yes, I'd say for the full year we've referenced roughly 30% expansion for the data segment, perhaps a touch higher. On the sequential side, Q4 consistently represents our biggest revenue quarter. In last year's Q4, a pullback invariably shows up in Q1, then it gradually ramps up across the year. As Eric points out, we don't expect that unit to keep expanding at 40% indefinitely; we'd look for a slight decline and a landing at or somewhat above 30% for the year.

Dan Arias

analyst
#21

All right, so if I understand correctly, that works out to roughly 20% expansion across the coming 2 quarters, correct? Essentially, you'd be cutting in half the pace you're seeing right now.

Jim Rogers

executive
#22

Growth will be a bit higher than that — it'll accelerate beyond it. What I'm telling you is it won't reach 40%.

Dan Arias

analyst
#23

All right.

Eric Lefkofsky

executive
#24

Looking ahead, we have no intention of working backward to give guidance split out by business unit every quarter. As for the data business, it's sitting in a really strong position.

Mark Massaro

analyst
#25

Hi everyone, nice work on the solid quarter. I'd like to ask about the liquid biopsy side of your business. I understand that xT in tissue accounts for most of the volume, but earlier this year a big company in this area released some pretty compelling data about the potential for adding time points in liquid. My question concerns your xF franchise. What sort of demand are you seeing when it comes to time points? Given that another fairly large player exists in this space, how do you feel about your competitive positioning? How would you assess your ability to go head-to-head with them?

Eric Lefkofsky

executive
#26

Sure. At a very high level, clearly our liquid growth rate has been far quicker than the rest of the market, since we operate at genuine scale. I believe we've said in the past that reductions represent roughly a third of the volume we take, or something along those lines, yes, 25%- 30%. That's meaningful. It makes up a substantial share of our volume, and our growth has outpaced the market by a lot. All things considered, from a therapy selection standpoint that franchise sits in a very strong position given what we've done historically. We hold an asset that we think stands fully competitive against others in the market when it comes to size and breadth, and so on. The emerging area of treatment response monitoring across multiple time points is something we're also examining. Our portfolio covers not only minimal residual disease measurement but also treatment response monitoring. Eventually, we'd expect this to become a larger portion of the market, though it also depends on reimbursements. With PRM you're basically in the same situation we face with MRD: absent payers covering it, you must limit volume. If not, you'd simply run a lot of tests while bringing in no revenue. We've stayed more disciplined than that. Down the road, these will create plenty of additional tailwind for our unit volume, but reimbursement is required. At present they're modest, yet our product set is extremely competitive.

Mark Massaro

analyst
#27

All right. The second thing I want to ask about is Ambry — definitely performing much better than what we had in our models. I believe you mentioned that other companies in this area are either leaving or maybe simply aren't paying the same kind of attention as before. So I'm wondering, did any money get put in — for example, did you invest anything into your commercial team during Q2 or before that? I'm just attempting to understand some of the positives and negatives that would account for such strong growth this quarter.

Eric Lefkofsky

executive
#28

What I'd say is that at a broad level, you can view that growth as roughly a 50/50 split — half coming from market share we're taking away from others who are sort of collapsing, and half from gains we're achieving on our own, or that the average person is achieving on their own, simply because the product is so good. We're getting the payoff from investments they've made over many years as they've essentially constructed a hereditary platform that is truly best-in-class, and a substantial portion of the market acknowledges it as truly best-in-class. An increasing number of large systems are switching over to Ambry since it's essentially the gold standard in that area. What people want is everything that goes along with it: the turnaround times, the best-in-class, you know, error rates, the technology they've built around it, the analysis that they deliver, the experience that they deliver; it's simply a really strong product. They've also put a huge amount of investment into Rare and Peds. We're extremely enthusiastic about how that product set is growing, and it remains fairly small in relative terms, but my guess is it will become a major driver across the coming several years. Our sense is that the core of the business, the core of the growth, feels durable and sustainable; we're not standing here saying, you know, you can count on 30% growth over the next five years. As we've attempted to do historically, we're going to stay conservative until we observe how these things unfold.

Mark Massaro

analyst
#29

Great. Thank you.

Andrew Brackmann

analyst
#30

Hi folks, good morning. Appreciate you taking the question. Pathos has been quite busy on the business development side during this year. It appears that a growing number of deals or partnerships are taking place within the space. Products are ending up in better places; as far as you two are concerned, how should we frame your willingness to keep pursuing acquisitions or partnerships across, let's say, the near to medium term? Thanks.

Eric Lefkofsky

executive
#31

Yeah, I'd say we've always operated opportunistically, though we haven't been especially acquisitive. My sense is we attempt to apply the same level of discipline to the companies we evaluate, whether that comes through a BD lens or a corporate debt lens, as we have applied when it comes to operating the business. We have no desire to throw off all the solid organic momentum we've built; going left after a long stretch of going straight isn't something we're interested in. My expectation is that we'll keep doing that. There are definitely a certain number of companies out there possessing interesting products, interesting teams, or interesting data sets that we examine, whether that's within our applications business, our data business, or our diagnostic business. We remain measured and disciplined. If you examine our last 6 or 7 years and the companies we've bought, I'd guess we'll generally follow a comparable playbook moving forward. The market is shifting rather dynamically; we're likewise conscious that, as these chess pieces move around, we don't want to end up in a worse spot than we would have been in otherwise.

Doug Schenkel

analyst
#32

Morning, and thanks for fielding this. I've got a few quick clarifications, and it's sort of a continuation of what Andrew asked. Is there a decent guideline for how you'll weigh partnerships against doing things in-house? Is the deciding factor how much of it involves technology? How much comes down to ROI? It'd help to hear a bit more detail on how you essentially work through that calculation. Then my second one also builds on MRD. I get that this becomes a larger piece of the narrative once we're in next year. What I'm wondering about is the coming few years. As a share of oncology volumes, what size do you anticipate MRD reaching? And what does that do to the gross margin path as time goes on? Thanks.

Eric Lefkofsky

executive
#33

Sure, I can take that. Let's begin at the top. Buying another company isn't what we're after. With a lengthy operating plan in place for reaching positive Adjusted EBITDA, we aren't seeking to purchase a business that sends us way back, where suddenly we'd say, "Oops, just joking." Our starting point is this: should we make an acquisition, we don't want it to throw off our in-house roadmap; that's the perspective we begin with. It's not that such a deal couldn't happen, but typically that's our frame; on top of that, as we've mentioned before, we're quite pleased with the diagnostics portfolio we have today. From hereditary through solid and liquid treatment selection to MRD plus monitoring and response, we believe we hold an extraordinarily thorough offering. Our sense is that the portfolio is quite expansive. It's not that we'd never eventually put more money into diagnostics, yet at this moment we certainly believe we're positioned well. A number of the possibilities we review could sit in the data business or the apps business. Once more, we don't intend to shift course in a way that significantly alters our operating plan. What you ought to anticipate is discipline from us regarding what we buy. What you ought to anticipate is synergy—filling some gap inside the company that strikes us as strategic and significant—rather than some wild pivot that pushes us backward in enormous fashion.

Jim Rogers

executive
#34

To add something there, many businesses we’ve reviewed over time were ones we’d have funded ourselves. They own something that clearly strengthens what we’re creating at Tempus. A number of those are essentially plug-and-play tech firms that we’ve examined.

Eric Lefkofsky

executive
#35

Okay, stepping back for a moment — I think it's important to point out that AI will, as I've said, bring about major disruption in this area. We have to give serious thought to what the landscape will look like when large language models and generative AI are driving incredible change. We could sit here and say, "Here's our plan as of today," but keep in mind that when the market shifts, we have to shift with it. I don't want someone coming back to me and saying, "But you told us this." At the end of the day, yes, we have a plan, but we've also proven very capable of reading the broader market and pivoting according to what we observe. One thing you should expect from a management team is that they won't be caught off guard down the road. On MRD, just briefly — and Jim can chime in — we believe we hold a genuinely strong portfolio spanning naive, informed, and MRD. This is an enormous space, and it's expanding. At present, it represents a fairly minor portion of our total business, since reimbursement isn't there. We aren't pursuing it at scale. If reimbursement comes through, which we anticipate it will, and if Personalis secures reimbursement, which is what they anticipate, then we will definitely put more investment behind driving that volume in 2026 and 2027. My expectation is that it will serve as a catalyst for our unit growth. Today, we're lucky that our units are climbing substantially even without it. When it comes to data growth, genomics growth, and ASP, we don't — we apply the same philosophy. When your business is expanding at this pace, throwing off this level of operating leverage at such a high gross margin, there's simply no pressure to say, "We need to raise ASP by another $300 as quickly as possible," or, "We need to force more unit growth right now as fast as we can." We're growing very rapidly. We're producing enormous leverage. The business is doing extremely well. As I mentioned in my letter, we actually take a different tack, which is: how do we keep this going not just in Q3 or Q4, but across the coming three to five years, seven to ten years? How do we accomplish that? Most of what we focus on as a management team comes down to building products and bringing them to market in ways that will deliver steady growth over long time horizons. If and when we encounter periods of extra tailwind, my expectation is that we'll aim to be measured about how quickly we press the accelerator and bring these offerings to market in the disciplined manner we've always maintained.

Jim Rogers

executive
#36

Yes, let me just mention as well that when it comes to margins, with the MRD launch, clearly we're limiting volumes at present since reimbursement isn't in place. Once reimbursements arrive, if there happens to be any effect on margin, we'd keep that in mind so we stay on the course we're already on regarding profitability. That same discipline Eric talked about, which we have now, will carry forward even after reimbursement is available, so that margins are maintained.

Eric Lefkofsky

executive
#37

Yeah, and just to give a bit more texture here — we're sitting in a really strong position, correct? Our company has numerous growth drivers. There are so many small pockets, you know, of possible future tailwinds or acceleration down the road, and that's fantastic, right? Our data business has a ton going on that might be catalytic. Our apps business has a ton going on that might be catalytic; MRD might be catalytic. Other products we're bringing to market might be catalytic, moving into new spaces like Rare and Peds that might be catalytic. There's a whole lot here that certainly, over time, ought to drive and propel how fast we grow. I'd far prefer a company growing at 25% across a decade over one growing at 50% this year and 10% the next. What we truly want is sustained growth over the long term. When we consider all the incredible things happening here, we consider layering them in a manner that generates that kind of sustainable growth.

Subbu Nambi

analyst
#38

Hi everyone, good morning, and thanks for letting me ask. First, I wanted to ask about a paper that came out not long ago, which described an AI algorithm built to do a better job of stratifying diabetes risk among patients based on HbA1c levels. Can you discuss how that algorithm came together, and what your expectations are regarding the timing and the setting where you might be able to sell it commercially? And related to that, when you consider the prospect of expanding your Insights platform business beyond oncology into other fields, how should we be thinking about that over a longer horizon? Thanks.

Eric Lefkofsky

executive
#39

Very briefly, given where I was, we hold an extremely wide-ranging portfolio of algorithms. Like we've said, there are many reasons we don't discuss this much. As this quarter's letter makes clear, we've been involved in roughly 2,000 publications, posters, papers, and so forth; our scientific and mathematical work runs very deep. Our product and engineering groups are quite big, and we employ a substantial number of PhDs and MDs. More than 1,000 technical staff members are here, working daily. These teams are sizable. We develop many algos; they get published, and they make their way into the market. What makes all of our algos difficult — most of them — is that right now we're up against a basic defect in how U.S. healthcare is structured. I'm not pointing fingers at anybody, but it's a basic defect: as a system, we currently lack any way to reimburse for AI or algorithms. There are ways to get paid for what you might call wet lab work. With chemistry and biology, payment is possible. When it comes to an AI insight, it's far, far tougher. The system is currently grappling with this. At the federal level, people are grappling with it. My guess is that eventually they'll figure out how to pay for these sorts of AI and data products — algos especially — since the things they can accomplish are simply remarkable. Occasionally you come across places where payment does happen; for instance, we've noted before how good it was to see Medicare, and CMS specifically, reimbursing our FDA-approved algorithms that run on top of electrocardiograms, and we now have 2 of those. We've got atrial fibrillation cleared, and low ejection fraction. Those are reimbursed at a listed rate of roughly $120 for each algo, which is excellent. Our expectation is that in time, hundreds of such products will be reimbursed, and rightly so, because they deliver not just incredible patient benefit but also incredible economic benefit. The math is straightforward, isn't it? You're able to pay for plenty of tests priced at $50 or $100. When they prevent a $100,000 heart attack or a $200,000 stroke, becoming strongly accretive to the healthcare system as a whole doesn't require much. Up until the point where these get reimbursed, everything here will stay fairly early-stage as far as our total financial picture goes, and we've been upfront about that. AI touches every area of what we do — diagnostics, data, all of it — but the portion of the business that is purely AI-driven algorithms will remain modest until payment comes through. If reimbursement happens and these offerings grow, we'd see some genuinely pleasant economic upside; we won't put that into guidance until it actually shows up; on the front of additional disease areas, our data sets are quite extensive in cardiology, radiology, and pathology, and neuropsych represents another expanding data set. Our oncology data set is bigger than anything else we have, which is why the bulk of our data products and AI work sits there. As time goes on, we'd expect that creating molecular data and developing diagnostic biomarkers will matter just as much across nearly all the big disease categories. I see no reason it wouldn't. Those things will likewise fuel our diagnostics operation over the long haul, along with our data operation. At present, oncology accounts for the majority of diagnostics, and oncology supplies the majority of data.

Elizabeth Krutoholow

executive
#40

Appreciate everyone taking the time to be with us today. We're here to answer anything you'd like to ask as a follow-up. We're eager to share our next update with you when the coming quarter arrives.

Operator

operator
#41

That wraps up our session for today, everyone. We appreciate each of you for taking part, and at this point you're free to leave the line.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.